Revolutionizing Medical Device Clinical Trials
MediDraft AI is the world's first artificial intelligence agent specifically designed for creating medical device clinical trial protocols. Unlike pharmaceutical-focused solutions, our platform addresses the unique regulatory challenges faced by medical device developers.
By leveraging advanced AI technology trained on extensive medical device regulatory data, Medidraft dramatically reduces preparation time by 70% and slashes costs by 50%, making global clinical trials accessible even to startups and small manufacturers.
Technology
Modular RAG-Based Search & Generation Engine
Our modular architecture enables precision tuning, easy component replacement, and rapid adaptation to regulatory changes. When guidelines evolve, Medidraft updates automatically, ensuring continued compliance.
Device Class-Specific Solutions (I, II, III)
Medidraft is structured to automatically apply the appropriate requirements based on device classification across regulatory bodies. Input your device parameters (country, class, trial objectives, control groups) and receive customized protocols with all mandatory elements, optimal structure, and relevant references.
Proprietary Dataset
Leveraging 730,000+ global clinical trials and 29,000 CRO profiles, we've curated a specialized medical device trial dataset with purpose-built metadata—far beyond what generic pharmaceutical solutions offer.
Social Impact
Empowering Small Medical Device Companies
By reducing financial and time barriers, Medidraft enables startups and SMEs to pursue FDA/EMA-certified clinical trials that were previously accessible only to large corporations with extensive resources. This democratization of clinical trial capability helps innovative solutions reach global markets regardless of company size.
Accelerating Healthcare Innovation
Regulatory automation shortens medical device development cycles across the industry. Faster innovation cycles translate to more breakthrough technologies reaching patients sooner, creating positive ripple effects including new job opportunities in medtech manufacturing and implementation.
Expanding Patient Treatment Access
Every week saved in trial preparation means patients access potentially life-changing treatments earlier. By streamlining the regulatory pathway, Medidraft helps innovative medical devices reach patients who need them most without unnecessary administrative delays.
Media Coverage
Medidraft AI has captured attention across industry publications and mainstream media for its revolutionary approach to medical device clinical trials. Our leadership team regularly contributes expert insights on regulatory AI, clinical trial optimization, and the future of medtech innovation.
Our innovative approach to solving longstanding industry challenges has been featured in specialized publications covering regulatory affairs, medical device development, and healthcare AI implementation. Media inquiries can be directed [email protected].
Intellectual Property & Recognition
Patent Portfolio
MEDIAIPLUS has secured 8+ patents covering essential clinical trial technologies, demonstrating our commitment to innovation and our technological leadership in the field:
- Keyword Prediction Systems (Patent #10-2318674)
- Data Matching & Classification (Patents #10-2521961, #10-2521963)
- Content Output Optimization (Patent #10-2571399)
- Clinical Visualization Tools (Patent #10-2571400)
- Advanced Annotation Systems (Patent #10-2591048)
- Rare Disease Document Similarity Analysis (Patents #10-2619062, #10-2713856)
Awards & Recognition
- Minister's Commendation for Healthcare Innovation
- DATA-Stars Awards Excellence Prize
- Challenge K-Startup Ministerial Award
- AI+Security Demo Day Grand Prize (KISA President's Award)
- Gyeonggi Province Governor's Award for Startup Excellence